ResoTher Pharma and Professor Mauro Perretti, William Harvey Research Institute, Barts and the London School of Medicine, is pleased to announce that the partners together have won a Translational Research grant in the amount of £ 489.000 from Barts Charity London. The partners will use the proceeds of the award to carry out pharmacological studies supporting the preclinical development of RTP-026, a peptide drug candidate originally discovered by Prof Perretti and colleagues.

Comments from ResoTher Pharma´s CEO Lone Veng: “We are extremely pleased with recently having received the valuable recognition of two prestigious funding bodies, as the grants from both Barts Charity and the Innovation Foundation are significant endorsements of our project approach and technology. The grant from Barts Charity provides an opportunity to collaborate with the excellent researchers at Barts and the London School of Medicine, one of the most recognized medical research universities in Europe. We are grateful for the high degree of external validation for our novel technology”.

About William Harvey Research Institute (WHRI): WHRI, a part of Barts and the London School of Medicine, is a specialized translational pharmacology institute founded by Nobel Laureate Sir John Vane, and focusing on cardiovascular, inflammatory and endocrinological science. Professor Perretti, now Dean of Research at Barts and the London school of Medicine, is former Co-director of WHRI and co-inventor of the RTP-026 compound. Thomas Jonassen is visiting Professor at WHRI and member of WHRI´s international Scientific Advisory Board. For more information visit www.qmul.ac.uk/whri/

About Barts Charity: Barts Charity is the dedicated charity of the five hospitals of the Barts Health NHS trust. Through their funding schemes they fund research and innovative healthcare initiatives which improve patient care. For more information visit www.bartscharity.org.uk